← All earnings call summaries
Viyash Scientific Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- API flat q-o-q due to timing; strong rebound expected in Q2; Animal API capacity expanded with US approvals
- FY27 capex Rs. 250-300 Cr; focus on R&D, manufacturing, and selective inorganic growth
- Q1 FY27 revenue Rs. 946 Cr +20% y-y; EBITDA Rs. 205 Cr +59% y-y; margin 21.6% +530 bps y-y; PAT Rs. 79 Cr +115% y-y
- High potent oncology API/formulation R&D progressing; revenues expected from 2029 onwards
- Minority interest ~17% of profits; plans to acquire full ownership in 1-2 years
- Animal Health formulation strong growth; domestic market +60%; new product launches and geo-expansion ongoing
- Net debt down to Rs. 86 Cr; net debt/EBITDA 0.1x vs 1x a year ago
- US Human formulation grew 60% y-y; margin improved via vertical integration and API sourcing from India
- BioForLife acquisition in Italy to close soon; adds 85 companion animal products and strong vet clinic coverage
- Management committed to compliance, governance, and disciplined capital allocation
📄 Source: View original transcript (PDF)
Get Viyash Scientific Limited earnings summaries on Telegram
Add Viyash Scientific Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.